Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140031/S209

Edwards Crimper (9600LDS23, 9600LDS26, 9600LDS29, 9750CM20, 9750CM23, 9750CM26, 9750CM29)

Edwards Lifesciences, LLC · Decision date Sep 23, 2026

FDA DECISIONP140031/S209

What did the FDA decide?

FDA records P140031/S209 as a supplement to PMA P140031, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 23, 2026.

FDA approval order statement

adoption of the Edwards Crimper into an existing validated sterilization cycle
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 23, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P140031/S209
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
OK30
Decision date
Sep 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P140031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140031 · Original PMA

    SAPIEN 3 TRANSCATHETER HEART VALVE AND ACCESSORIES

  2. P140031/S209 received

    Application receipt date recorded by FDA.

  3. P140031/S209 · FDA decision

    30-Day Notice

  4. P140031/S202 · Related supplement

    Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve

  5. P140031/S210 · Related supplement

    Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX), Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX)

Timeline entries are records held by MedtechLedger for P140031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140031

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records